Effect of equivalent on-treatment apolipoprotein levels on outcomes (from the AIM-HIGH and HPS2-THRIVE)

Am J Cardiol. 2013 Nov 15;112(10):1697-700. doi: 10.1016/j.amjcard.2013.07.030. Epub 2013 Aug 30.

Authors

Mohammed Al-Hijji¹, Seth S Martin, Parag H Joshi, Steven R Jones

Affiliation

¹ Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland.

PMID: 23993116
DOI: 10.1016/j.amjcard.2013.07.030

No abstract available

Publication types

Editorial

MeSH terms

Apolipoproteins / blood*
Atherosclerosis / blood
Atherosclerosis / drug therapy*
Humans
Hypolipidemic Agents / therapeutic use*
Randomized Controlled Trials as Topic*
Treatment Outcome

Substances

Apolipoproteins
Hypolipidemic Agents